Medivation Inc.

(MDVN) Trade

By |


Medivation Inc was formed in Delaware in October 1995. The Company is a biopharmaceutical company engaged in the rapid development of novel small molecule drugs to treat diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc., or Astellas, the Company is developing XTANDI enzalutamide capsules. Together with Astellas, it is also conducting multiple trials of enzalutamide in earlier prostate cancer disease states, including the Phase 3 PREVAIL trial in patients with mCRPC who have not received chemotherapy, or pre-chemotherapy mCRPC patients, and in patients with breast cancer. Based on the positive results of the AFFIRM trial, the Company has exercised its right under its collaboration agreement with Astellas to co-promote XTANDI in the U.S., should it receive marketing approval. Their subsidiaries are Medivation Prostate Therapeutics Inc or MPT, Medivation Neurology Inc or MNI, Medivation Technologies Inc, or MTI, Medivation Field Solutions, Inc., or MFSI, and Medivation Services, Inc., or MSI. MPT holds the intellectual property rights covering XTANDI. MNI holds the intellectual property rights covering dimebon, which was in development for Alzheimer's disease and Huntington disease under its former collaboration with Pfizer. MTI holds the intellectual property rights covering its early-stage technologies. MFSI provides commercialization services to the Company, and MSI provides research and development services. It has received "Fast Track" designation from the U.S. Food and Drug Administration for the post-docetaxel indication. The Company is conducting this program in collaboration with Astellas.

Contact Information

Main Phone: +1 415 543-3470
Address: 36th Floor, 525 Market Street
State: CA
City / Town: San Francisco
Country: USA
Postal Code: 94105

Issuer Information

Exchange: NGS
Employees: 628
NAICS: Biological Product (except Diagnostic) Manufacturing(325414)
Company data no longer available
Last Price N/A Change $ N/A Change % N/A Tick N/A
Bid N/A Bid Size 0.00 Ask N/A Ask Size 0.00
Open N/A High N/A Low N/A Prev Close N/A
Last Trade Volume 0 52 Wk Hi 81.48 52 Wk Low 26.41
Market Cap N/A Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 165,928,674.00 EPS (TTM) -1.10 PE Ratio N/A Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 0 0
Number of Buys 0 0
Number of Sells 0 0
Net Activity 0 0
Last 10 Buys Shares
W. Anthony Vernon 1,000
Kathryn E. Falberg 1,000
Kathryn E. Falberg 1,000
Kathryn E. Falberg 1,000
Kathryn E. Falberg 1,000
Gregory H. Bailey 1,000
Gregory H. Bailey 1,000
Last 10 Sell Shares
Andrew K. W. Powell 1,000
Dawn Svoronos 1,000
Mohammad Hirmand 1,000
David T. Hung 1,000
Richard A. Bierly 1,000
Richard A. Bierly 1,000
David T. Hung 1,000
C. Patrick Machado 1,000
C. Patrick Machado 1,000
C. Patrick Machado 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 81.5 81.5 81.5 81.5
Low Target Price Estimate 40 40 40 40
Mean Target Price Estimate 71.54 71.54 71.54 71.54
Standard Deviation 13.02 13.02 13.02 13.02
Date of Most Recent Estimate 08/29/16 08/29/16 08/29/16 08/29/16
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 2 3 9 9
Moderate Buy 0 0 0 0
Hold 11 11 4 4
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 2.69 2.57 1.62 1.62